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Background: Chronic Kidney Disease (CKD) is associated with an increased risk for
stent thrombosis and adverse events following percutaneous coronary intervention
(PCI). High platelet reactivity (HPR) is also an independent correlate of thrombotic
events post PCI. Although CKD modulates platelet function, the impact of CKD on
HPR remains controversial, and whether or not HPR confers a differential risk for
MACE between CKD and non-CKD patients is unknown.
Methods: We performed a post-hoc analysis of the ADAPT-DES registry, which
included 8,583 patients (8,449 of whom had baseline serum creatinine measures)
undergoing PCI with successful DES placement. All patients underwent platelet
function testing using the VerifyNow assay. HPR was deﬁned as platelet reactivity
units (PRU) 208. CKD was deﬁned as a creatinine clearance <60 mL/min. We
compared the frequency and impact of HPR on MACE between CKD and non-CKD
patients.
Results: Patients with CKD (n¼1,395; 16.5%) were older and more often female and
diabetic, and had a lower ejection fraction compared to their non-CKD counterparts
(n¼7,054). Unadjusted HPR prevalence was higher among those with vs. without
CKD (48.9% vs. 41.5%, P<0.001). However, after multivariable adjustment this
association was attenuated and no longer signiﬁcant. While 1-year MACE rates were
higher among those with vs. without CKD (6.6% vs. 3.6%, P<0.001), the adverse and
incremental impact of HPR on MACE was uniform across CKD strata (pint ¼ NS for
all endpoints, Table 1).
Conclusions: While HPR is more common among those with CKD, this association
appears largely attributable to confounding risk factors that are more prevalent in these
patients. The incremental impact of HPR on MACE is similar among those with and
without CKD.Table 1. Adjudicated Events to 1-Year
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Stent
thrombosis
(deﬁnite/
probable)
1.8% (12) 0.6% (4) 3.18 [1.03,
9.87]
1.2% (33) 0.5% (20) 2.34 [1.34,
4.08]
Cardiac
death or MI
7.3% (48) 5.6% (39) 1.31 [0.86,
1.99]
4.2% (121) 2.9% (117) 1.47 [1.14,
1.89]
MACE* 10.9% (71) 8.1% (56) 1.35 [0.95,
1.92]
7.1% (202) 5.8% (232) 1.24 [1.03,
1.50]
MACE2** 7.3% (48) 5.6% (39) 1.31 [0.86,
1.99]
4.4% (127) 2.9% (119) 1.52 [1.18,
1.95]
*MACE ¼ cardiac death, MI, or clinically driven TLR; **MACE2 ¼ cardiac death, MI, or deﬁ-
nite/probable ST
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Background: Premature discontinuation of antiplatelet therapy after percutaneous
coronary intervention is known to predict stent thrombosis (ST). We aimed to
compare the impact of early versus late antiplatelet therapy discontinuation on ST in
patients receiving ﬁrst- and second-generation drug-eluting stents (DES).
Methods: A total of 6587 patients undergoing PCI with DES were analyzed, of which
4580 received 1st-generation DES (Cypher or Taxus) and 2007 received 2nd-gener-
ation DES (Xience or Promus). Patients were categorized into timing of clopidogrel
discontinuation within 1 year (never, <3 months, 3-12 months). The 1-year ARC-
deﬁned deﬁnite or probable ST was analyzed.
Results: In patients with 1st-generation DES, 536 (11.7%) had clopidogrel dis-
continued, 173 (3.8%) within ﬁrst 3 months and 363 (7.9%) at 3-12 months.
Cumulative 1-year ST rates were 1.0%, 13.6%, 3.0% (p <0.001) for never,
<3 months, 3-12 months discontinued, respectively. (Figure A) In patients with 2nd-
generation DES, 214 (11.9%) had clopidogrel discontinued, 94 (4.7%) within ﬁrst
3 months and 120 (5.9%) at 3-12 months. Cumulative 1-year ST rates were 0.1%,
5.4%, 0% (p <0.001) for never, <3 months, 3-12 months discontinued, respectively.
(Figure B).
Conclusions: Early clopidogrel discontinuation signiﬁcantly increases the risk of ST
after percutaneous coronary intervention in both 1st- and 2nd-generation DES. The
impact of clopidogrel discontinuation on ST appears to attenuate with the use of 2nd-
generation DES.TCT-8
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Background:While newer drug eluting stent (DES) promote more favorable vascular
healing, the optimal duration of dual antiplatelet therapy (DAPT) after implantation
with 2nd generation drug-eluting coronary stents remains undetermined. We aimed to
test whether 6-month DAPT would be non-inferior clinical and angiographic outcome
to 12-month DAPT after implantation of Zotarolimus-eluting stent (ZES) and
biolimus-eluting stent (BES).
Methods: This is a prospective, double-randomized, open-label, multicenter trial to
compare clinical events between 6-month DAPT and 12-month DAPT (in a 1:1 ratio),
and to demonstrate the non-inferiority of BES compared with ZES stents (in 1:1 ratio),
angiographically. Currently, 1055 patients were randomly assigned. The primary end
point was a major adverse cardiac events (MACE) at 12 months. Optical coherence
tomography (OCT) at 6 month was performed in 30 patients of each group. The
primary endpoint was MACE, secondary end points are target lesion failure, in-
segment LL at 12 months, and neointimal hyperplasia (NIH) by OCT at 6 month.acts/ORAL/Antiplatelet Agents B3
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follow-up in 526 patients (608 lesions). The primary endpoints were not statistically
different between the 6- and 12-month DAPT groups, including MACE (4.6 vs. 3.4%;
p ¼0.49) and stent thrombosis (0.0 vs. 0.3%; p ¼ 0.71), and MACE (3.4 vs. 4.6%;
p ¼0.49) and stent thrombosis (0.3 vs. 0.0%; p ¼ 0.71), according as type of stents
(BES vs. ZES, respectively). The secondary endpoints also were not signiﬁcantly
different between the 6- and 12-month DAPT groups, including target lesion failure
(2.0 vs. 1.6%; p¼ 0.53), in-segment LL (mm) at 12 months (0.090.37 vs. 0.050.39,
p ¼0.61). Similar results were shown between stents type. And NIH CSA (mm2) at
6month between BES and ZES were 0.380.28, 0.450.32, respectively (p¼0.41).
Conclusions: Six-month DAPT did not increase the risk of MACE, stent thrombosis,
target lesion failure, and LL at 12 months after implantation of drug-eluting stents
compared with 12-month DAPT. The 2nd generation DES including BES and ZES are
comparably efﬁcacious. Our results need to be conﬁrmed in larger trials and further
follow up data.
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Background: On-treatment platelet reactivity to clopidogrel is variable and in part
genetic dependent. In African American (AA) patients, the relation between on-
treatment platelet reactivity to clopidogrel and the factors that inﬂuence this interaction
are unknown. The present study aims to evaluate on-treatment platelet reactivity to
clopidogrel in AA patients and its interaction to race and CYP2C19*2 loss of function
mutation.
Methods: The study cohort included 289 consecutive patients presenting for percu-
taneous coronary intervention (PCI) who were entered into a prospective, observa-
tional registry. High on-treatment platelet reactivity (HTPR) was deﬁned as P2Y12
reaction units (PRU) 208 with VerifyNow P2Y12 assay and >50% by vasodilator-
stimulated phosphoprotein phosphorylation assay platelet reactivity index (VASP
PRI) measured 6-24 hours post-procedure. CYP2C19*2 (rs4244285) genotype was
analyzed by real-time polymerase chain reaction.
Results: The prevalence of HTPR by both PRU (56% vs. 35%, p¼0.003) and VASP
PRI (67% vs. 45%, p¼0.002) is more common in AA compared to Caucasians,
respectively. AA patients had higher on-treatment, mean PRU (207110 vs.
160102, p¼0.002) and VASP PRI (4926 vs. 3826, p¼0.004). AA also had
a higher prevalence of CYP2C19*2 allele carrier status compared to Caucasians
(43% vs. 29%, p¼0.04). AA race (p¼0.008) and CYP2C19*2 allele status (p¼0.02)
independently had signiﬁcant effects on PRU and VASP. Multivariable logistic
regression analysis has shown that both CYP2C19*2 allele carrier status and AA race
were independent correlates of HTPR for PRU 208.On-treatment Platelet Reactivity and CYP2C19*2 allele Carrier
Status by Race
Variable [n (%) or
meanSD]
African American Caucasian
(n=61) (n=228) p value
VerifyNow aspirin
ARU
41963 42059 0.9
HTPR by ARU550 6(9.8%) 22(9.9%) 0.99
VerifyNow PRU 207110 160102 0.002
HTPR by PRU208 34(56%) 80(35%) 0.003
HTPR by PRU230 28(46%) 62(27%) 0.005
HTPR by PRU250 27(44%) 47(21%) <0.001
VASP PRI 4926 3826 0.004
HTPR by VASP
PRI>50%
41(67%) 103(45%) 0.002
Carrier of
CYP2C19*2 allele
(AA/AG)
26(43%) 66(29%) 0.04
HTPR, high on-treatment platelet reactivity; ARU, aspirin reaction units; PRU, P2Y12 reaction
units; VASP PRI, vasodilator-stimulated phosphoprotein phosphorylation assay platelet reac-
tivity index
B4 JACC Vol 62/18/Suppl B j October 27–NovembConclusions: AA patients undergoing PCI not only have a higher prevalence of
HTPR to clopidogrel but also have higher CYP2C19*2 allele carrier status compared
to Caucasians. Careful selection of antiplatelet agents should be considered in an AA
population at higher risk for ischemic complications.
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Background: Comparative effectiveness studies may seek to enroll geographically
diverse populations to enhance generalizability. We compared enrollment, randomi-
zation, drug and device utilization between US and non US patients across a large
international trial.
Methods: The Dual Antiplatelet Therapy (DAPT) Study is a double-blind randomized
trial designed to compare durations of DAPT after PCI with stents with respect to
clinical events. Patients were enrolled between August 2009 and July 2011. At 12
months, eligible patients were randomized to receive placebo+aspirin or thienopyr-
idine+aspirin through study endpoint (30 months). We compared patient and procedure
characteristics, patterns of stent and medication choice, compliance with antiplatelet
therapy, and randomization rates, between patients enrolled in the US and other
countries.
Results: The DAPT Study enrolled 26,194 patients treated with drug-eluting (N¼
23,210) or bare metal (N¼2,984) stents, 23,495 in the US (90%) and 2,699 in other
countries: UK 629, Poland 388, Germany 372, Romania 312, Hungary 271, New
Zealand 239, Australia 197, France 101, Canada 96, and Czech Republic 94. Non-US
patients were more likely to be male, current smokers, present with acute coronary
syndrome, receive bare metal vs drug-eluting stents, clopidogrel vs prasugrel, and
aspirin doses 100 mg daily (each p<0.001). At 12m, non-US patients were more
likely to be DAPT compliant (94.7 vs 89.2%, p<0.001). Non-US patients were more
likely to be randomized (65% vs 43%, p <0.001), even after adjusting for baseline
characteristics (OR¼ 2.27; p<0.001).
Conclusions: Within the DAPT Study, non-US patients were more likely to be
compliant with study procedures, independent of patient characteristics. Regional
variation in patient characteristics, compliance, and practice patterns observed in
broadly inclusive clinical trials allows for the evaluation of interactions between these
factors and treatment effectiveness.Bare Metal and Drug-Eluting Stents
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